565 related articles for article (PubMed ID: 29066452)
1. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L;
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
3. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.
Stewart RAH; Hagström E; Held C; Wang TKM; Armstrong PW; Aylward PE; Cannon CP; Koenig W; López-Sendón JL; Mohler ER; Hadziosmanovic N; Krug-Gourley S; Ramos Corrales MA; Siddique S; Steg PG; White HD; Wallentin L;
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862971
[TBL] [Abstract][Full Text] [Related]
4. Darapladib for preventing ischemic events in stable coronary heart disease.
; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
[TBL] [Abstract][Full Text] [Related]
5. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Hilvo M; Wallentin L; Ghukasyan Lakic T; Held C; Kauhanen D; Jylhä A; Lindbäck J; Siegbahn A; Granger CB; Koenig W; Stewart RAH; White H; Laaksonen R;
J Am Heart Assoc; 2020 May; 9(10):e015258. PubMed ID: 32375553
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
Batra G; Ghukasyan Lakic T; Lindbäck J; Held C; White HD; Stewart RAH; Koenig W; Cannon CP; Budaj A; Hagström E; Siegbahn A; Wallentin L;
JAMA Cardiol; 2021 Dec; 6(12):1440-1445. PubMed ID: 34431970
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
Lindholm D; Lindbäck J; Armstrong PW; Budaj A; Cannon CP; Granger CB; Hagström E; Held C; Koenig W; Östlund O; Stewart RAH; Soffer J; White HD; de Winter RJ; Steg PG; Siegbahn A; Kleber ME; Dressel A; Grammer TB; März W; Wallentin L
J Am Coll Cardiol; 2017 Aug; 70(7):813-826. PubMed ID: 28797349
[TBL] [Abstract][Full Text] [Related]
10. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
[TBL] [Abstract][Full Text] [Related]
11. Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome.
Barger LK; Rajaratnam SMW; Cannon CP; Lukas MA; Im K; Goodrich EL; Czeisler CA; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29018021
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
Held C; White HD; Stewart RAH; Davies R; Sampson S; Chiswell K; Silverstein A; Lopes RD; Heldestad U; Budaj A; Mahaffey KW; Wallentin L;
Am Heart J; 2019 Feb; 208():65-73. PubMed ID: 30572273
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.
Stewart RAH; Held C; Krug-Gourley S; Waterworth D; Stebbins A; Chiswell K; Hagstrom E; Armstrong PW; Wallentin L; White H
J Am Heart Assoc; 2019 Apr; 8(7):e010641. PubMed ID: 30897999
[TBL] [Abstract][Full Text] [Related]
14. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
Hagström E; Held C; Stewart RA; Aylward PE; Budaj A; Cannon CP; Koenig W; Krug-Gourley S; Mohler ER; Steg PG; Tarka E; Östlund O; White HD; Siegbahn A; Wallentin L;
Clin Chem; 2017 Jan; 63(1):325-333. PubMed ID: 27811204
[TBL] [Abstract][Full Text] [Related]
15. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.
Correa S; Morrow DA; Braunwald E; Davies RY; Goodrich EL; Murphy SA; Cannon CP; O'Donoghue ML
J Am Heart Assoc; 2018 Oct; 7(20):e009077. PubMed ID: 30371283
[TBL] [Abstract][Full Text] [Related]
16. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
17. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.
Wallentin L; Eriksson N; Olszowka M; Grammer TB; Hagström E; Held C; Kleber ME; Koenig W; März W; Stewart RAH; White HD; Åberg M; Siegbahn A
PLoS Med; 2021 Jan; 18(1):e1003513. PubMed ID: 33439866
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Guimarães PO; Granger CB; Stebbins A; Chiswell K; Held C; Hochman JS; Krug-Gourley S; Lonn E; Lopes RD; Stewart RAH; Vinereanu D; Wallentin L; White HD; Hagström E; Danchin N
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28912210
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Eisen A; Cannon CP; Braunwald E; Steen DL; Zhou J; Goodrich EL; Im K; Dalby AJ; Spinar J; Daga S; Lukas MA; O'Donoghue ML
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28077384
[TBL] [Abstract][Full Text] [Related]
20. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
